Compare JHS & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JHS | ELTX |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.5M | 209.9M |
| IPO Year | 1994 | 2014 |
| Metric | JHS | ELTX |
|---|---|---|
| Price | $11.01 | $12.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 17.6K | ★ 138.2K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.62 | $4.60 |
| 52 Week High | $12.09 | $14.93 |
| Indicator | JHS | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 24.22 | 56.75 |
| Support Level | $11.01 | $7.78 |
| Resistance Level | $11.40 | $12.52 |
| Average True Range (ATR) | 0.10 | 1.17 |
| MACD | -0.03 | -0.12 |
| Stochastic Oscillator | 4.62 | 30.02 |
John Hancock Income Securities Trust is a United States-based closed-end diversified management investment company. Its main objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.